Skip main navigation
We use cookies to give you a better experience, if that’s ok you can close this message and carry on browsing. For more info read our cookies policy.
We use cookies to give you a better experience. Carry on browsing if you're happy with this, or read our cookies policy for more information.

Skip to 0 minutes and 9 secondsHere at St. George's, I'm a clinical scientist, trained in classical cytogenetics. My current position is I'm training officer, so I oversee the training of all the genetic technologists and scientists in the laboratory. The array technology has actually been around since the early '90s. However, for the arrays to reach the diagnostic laboratory setting and certainly here at St. George's, we started in around 2011. A number of other laboratories were before that. So generally, within the NHS diagnostic setting, around 2009 onwards. Array CGH-- Array Comparative Genome Hybridisation, to give it its full title-- actually involves comparing a patient's DNA sample against a reference DNA sample. And the reference DNA sample is perceived to be a normal sample, without any abnormalities being present.

Skip to 1 minute and 7 secondsSo when you're comparing a patient's DNA against that, what you're looking for is any losses or gains in the patient that obviously aren't present there in the reference DNA and therefore would indicate that there's an imbalance in the patient's DNA. Comparing array CGH to conventional cytogenetics or G-banding karyotype analysis-- essentially, they're both a whole-genome analysis, which means you're looking across the whole of the 22 chromosomes, plus the X and Y, unlike targeted molecular testing. So we're looking across all the DNA of a patient. The difference between array CGH and karyotyping is the resolution at which you're doing this.

Skip to 1 minute and 50 secondsSo in terms of G-banded analysis, what we're able to detect there, in terms of losses, is something in the region of four to five megabases of DNA, which actually can take out 30, 40 genes. In array CGH, we're down to the gene level and can actually look within certain genes-- at just portions of those genes. So there's a far difference in resolution. So array analysis-- we're probably down to about 100kb-- is our baseline detection rate. One of the advantages that CGH offers over conventional karyotyping is the detection of the abnormality rate. Conventional karyotyping will detect abnormalities in around 10% of patients. With array CGH, we can detect abnormalities in 20% or even 25% of patients.

Skip to 2 minutes and 44 secondsSo in terms of offering a diagnosis to the patient, it's a much more powerful tool. The limitations of array CGH are that it won't detect balance rearrangements in a patient. It won't detect triploidy. It's not very good at detecting mosaicism. Also, what it can detect is very much dependent on the platform that you use. The higher the resolution of the platform, the more that you can detect. You can detect copy number changes down to the gene level. But obviously at nucleotide level, array CGH can't detect those. One of the other limitations is that we may not be able to interpret what we find on array CGH. Some of the changes, yes, correlate with known pathogenic syndromes.

Skip to 3 minutes and 32 secondsHowever, a number of the changes that we may see we can't interpret. And so, in terms of patient diagnosis, they're not necessarily any further forward.

Looking at chromosomes

Karen Marks, senior clinical scientist in cytogenetics, discusses the impact that array CGH (Array Comparative Genomic Hybridization) has had on clinical practice.

Karen describes the process of array CGH, where a patient’s DNA sample is compared against the reference DNA, that is considered to have no abnormalities. She also explains how to spot the imbalances in patients’ DNA.

Share this video:

This video is from the free online course:

The Genomics Era: the Future of Genetics in Medicine

St George's, University of London

Get a taste of this course

Find out what this course is like by previewing some of the course steps before you join:

  • Welcome to Week 1
    Welcome to Week 1
    video

    In this video, Lead Educator, Dr Kate Tatton-Brown welcomes learners to the course and explains the course aims and outcomes.

  • Did you know?
    Did you know?
    video

    Our resident scientist tells you his favourite genomics facts.

  • Errors in recombination
    Errors in recombination
    article

    This video describes how structural chromosome abnormalities occur when errors occur in recombination.

  • Responsibility in the genomic era
    Responsibility in the genomic era
    video

    In this tutorial, you will hear from Dr Carwyn Rhys Hooper on the concept of responsibility for health.

Contact FutureLearn for Support